Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

Detalles Bibliográficos
Autores principales: Evans, D. Gareth, Howell, Sacha J., Howell, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784814/
https://www.ncbi.nlm.nih.gov/pubmed/31444676
http://dx.doi.org/10.1007/s10689-019-00142-8
_version_ 1783457811300089856
author Evans, D. Gareth
Howell, Sacha J.
Howell, Anthony
author_facet Evans, D. Gareth
Howell, Sacha J.
Howell, Anthony
author_sort Evans, D. Gareth
collection PubMed
description
format Online
Article
Text
id pubmed-6784814
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-67848142019-10-17 Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy? Evans, D. Gareth Howell, Sacha J. Howell, Anthony Fam Cancer Editorial Springer Netherlands 2019-08-23 2019 /pmc/articles/PMC6784814/ /pubmed/31444676 http://dx.doi.org/10.1007/s10689-019-00142-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Editorial
Evans, D. Gareth
Howell, Sacha J.
Howell, Anthony
Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
title Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
title_full Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
title_fullStr Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
title_full_unstemmed Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
title_short Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
title_sort should unaffected female brca2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784814/
https://www.ncbi.nlm.nih.gov/pubmed/31444676
http://dx.doi.org/10.1007/s10689-019-00142-8
work_keys_str_mv AT evansdgareth shouldunaffectedfemalebrca2pathogenicvariantcarriersbetoldthereislittleornoadvantagefromriskreducingmastectomy
AT howellsachaj shouldunaffectedfemalebrca2pathogenicvariantcarriersbetoldthereislittleornoadvantagefromriskreducingmastectomy
AT howellanthony shouldunaffectedfemalebrca2pathogenicvariantcarriersbetoldthereislittleornoadvantagefromriskreducingmastectomy

Ejemplares similares